Covid Report: Biotech Pops On Coronavirus Deal; Gilead Builds Drug Supply

Covid Report: Biotech Pops On Coronavirus Deal; Gilead Builds Drug Supply

Vir Biotechnology stock popped Monday after the biotech company inked a deal with GlaxoSmithKline to develop coronavirus treatments. Gilead Sciences says it's stockpiling remdesivir.